Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A

Archivum Immunologiae et Therapiae Experimentalis

Volumn 53, Issue 4, 2005, Pages 352-356

  Sawecka, Jadwiga ^a   Skulimowska, Joanna ^a   Windyga, Jerzy ^a   Łopaciuk, Stanisław ^a   Kościelak, Jerzy ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Cryoprecipitate; Factor VIII concentrates; Hemophilia A; Inhibitor in hemophilia; Intron 22 inversions

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; BETHESDA ASSAY; BIOASSAY; CHILD; CHROMOSOME INVERSION; CRYOPRECIPITATE; DISEASE SEVERITY; FACTOR VIII GENE; GENE; GENE MUTATION; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; INTRON; MAJOR CLINICAL STUDY; POLAND; SOUTHERN BLOTTING; TRANSFUSION;

ADOLESCENT; ADULT; AGED; BLOOD TRANSFUSION; BLOTTING, SOUTHERN; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FIBRINOGEN; HEMOPHILIA A; HUMANS; INTRONS; INVERSION, CHROMOSOME; MIDDLE AGED; MUTATION; POLAND; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 31944432356     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Antonarakis S. E., Rossiter J. P., Young M., Horst J., de Moerloose P., Sommer S. S. and Ketterling R. P. (1995): Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood, 86, 2206-2212.
2. Auerswald G., Spranger T. and Brackmann H. H. (2003): The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 88, EREPO5.
3. Bagnall R. D., Waseem N., Green P. M. and Giannelli F. (2002): Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood, 99, 168-174.
4. Behrmann M., Pasi J., Saint-Remy J. M., Kotitschke R. and Kloft M. (2002): Von Willebrand factor modulates Factor VIII immunogenicity: comparative study of different Factor VIII concentrates in a haemophilia A mouse model. Thromb. Haemost., 88, 221-229.
5. Brinke A., Tagliavacca L., Naylor J., Green P., Giangrande P. and Gianelli F. (1996): Two chimaeric transcription units result from an inversion breaking intron 1 of the factor VIII gene and a region reportedly affected by reciprocal translocations in T-cell leukaemia. Hum. Mol. Genet., 5, 1945-1951.
6. El Alfy M. S., Tantawy A. A., Ahmed M. H. and Abdin I. A. (2000): Frequency of inhibitor development in severe hemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction. Haemophilia, 6, 635-638.
7. European Study Group of Factor VIII Antibody (1979): Development of factor VIII antibody in haemophilic monozygotic twins. Scand. J. Haematol., 23, 64-68.
8. Ghosh K., Shetty S., Kulkarni B., Nair S., Pawar A., Khare A., Baindur S. and Mohanty D. (2001): Development of inhibitors in patients with haemophilia from India. Haemophilia, 7, 273-278.
9. Goodeve A. C., Preston F. E. and Peake I. R. (1994): Factor VIII gene rearrangements in patients with severe hemophilia A. Lancet, 343, 329-330.
10. Kasper C. K., Aledort L., Aronson D., Counts R., Edson J. R., van Eys J., Fratantoni J., Green D., Hampton J., Hilgartner M., Levine P., Lazerson J., McMillan C., Penner J., Shapiro S. and Shulman N. R. (1975): Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb. Diath. Haemorrh., 34, 612.
11. Kreuz W., Escuriola-Ettingshausen C., Martinez-Saguer I., Güngör T. and Kornhuber B. (1996): Epidemiology of inhibitors in haemophilia A. Vox Sang, 70, (suppl. 1), 2-8.
12. Kreuz W., Ettingshausen C. E., Auerswald G., Saguer I. M., Becker S., Funk M., Heller C., Klarmann D., Klingebiel T. and GTH PUP Study Group (2003): Epidemiology of inhibitors and current treatment strategies. Haematologica, 88, EREP04.
13. Kreuz W., Ettingshausen C. E., Zyschka A., Oldenburg J., Saguer I. M., Ehrenforth S. and Klingebiel T. (2002) Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin. Thromb. Hemost., 28, 285-290.
14. Lakich D., Kazazian H. H. Jr., Antonarakis S. E. and Gitschier J. (1993): Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat. Genet., 5, 236-241.
15. Laub R., Di Giambattista M., Fondu P., Brackmann H. H., Lenk H., Saenko E. L., Felch M. and Scandella D. (1999): Inhibitors in German haemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Thromb. Haemost., 81, 39-44.
16. Lusher J. M. (2002): First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin. Thromb. Hemost, 28, 273-276.
17. Naylor J., Brinke A., Hassock S., Green P. M. and Giannelli F. (1993): Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. Hum. Mol. Genet., 2, 1773-1778.
18. Oldenburg J., Brackmann H. H. and Schwaab R. (2000): Risk factors for inhibitor development in hemophilia A. Haematologica, 85 (suppl. 10), 7-14.
19. Oldenburg J., El-Maarri O. and Schwaab R. (2002): Inhibitor development in correlation to factor VIII genotypes. Haemophilia, 8 (suppl. 2), 23-29.
20. Oldenburg J., Schröder J., Brackmann H. H., Müller-Reibe C., Schwaab R. and Tuddenham E. (2004): Environmental and genetic factors influencing inhibitor development. Semin. Hematol., 41 (suppl. 1), 82-88.
21. Peerlinck K., Arnout J., Gilles J. G., Saint-Remy J. M. and Vermylen J. (1993): A higher than expected incidence of Factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized Factor VIII concentrate. Thromb. Haemost., 69, 115-118.
22. Peerlinck K., Rosendaal F. R. and Vermylen J. (1993): Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood, 81, 3332-3335.
23. Rosendaal F. R., Nieuwelhuis H. K., van den Berg H. M., Heijboer H., Mauser-Bunschoten E. P., van der Meer J., Smit C., Strengers P. F. and Briet E. (1993): A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood, 81, 2180-2186.
24. Rossiter J. P., Young M., Kimberland M. L., Hutter P., Ketterling R. P., Gitschier J., Horst J., Morris M. A., Schaid D. J. and de Moerloose P. (1994): Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum. Mol. Genet., 3, 1035-1039.
25. Saenko E. I., Ananyeva N. M., Kouiavskaia D. V., Khrenov A. V., Anderson J. A., Shima M., Qian J. and Scott D. (2002): Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia, 8, 1-11.
26. Sawecka J., Skulimowska J. and Kościelak J. (2000): Inversion mutations in patients with severe hemophilia A. Acta Haematol. Pol., 31, 47-50.
27. Scharrer I., Bray G. L. and Neutzling O. (1999): Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 5, 145-154.
28. Schwaab R. Brackmann H. H., Meyer C., Seehafer J., Kirchgesser M., Haack A., Olek K., Tuddenham E. G. and Oldenburg J. (1995): Haemophilia A: mutation type determines risk of inhibitor formation. Thromb. Haemost., 74, 1402-1406.
29. Sharathkumar A., Lillicrap D., Blanchette V. S., Kern M., Leggo J., Stain A. M., Brooker L. and Carcao M. D. (2003): Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J. Thromb. Haemost., 1, 1228-1236.
30. Tizzano E. F., Cornet M. and Baiget M. (2003): Inversion of intron 1 of the factor VIII gene for direct molecular diagnosis of hemophilia A. Haematologica, 88, 118-120.